Dr. Kottil W. Rammohan, MD
Neurology (Neurology Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
FL license ME 107082
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 5 companies reported 14 payments worth $10,363 in total to this clinician.
| EMD Serono, Inc. | $9,847 |
|---|---|
| Amgen Inc. | $204 |
| Tg Therapeutics, Inc. | $155 |
| Biogen, Inc. | $127 |
| Sandoz Inc. | $29.49 |
| Compensation for services other than consulting (speaking, faculty) | $9,240 |
|---|---|
| Food and Beverage | $1,110 |
| Education | $12.56 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| EMD Serono, Inc. Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaking Services (Fee For Service) | $9,240 |
| EMD Serono, Inc. Jun 11, 2025 | Education in-kind Company’s descriptionReprints | $12.56 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $476,555 in research payments for these studies, mostly to the institutions running them.
- Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE
F. Hoffmann-la Roche AG - A Phase 2 3, Open label, Historical controlled, Single arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin 4 antibo…
Alexion Pharmaceuticals, Inc. - A Phase 3, External Placebo Controlled, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Alexion Pharmaceuticals, Inc. - A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Genzyme Corporation · Active, not recruiting · NCT06372145 - A phase iii study to evaluate the efficacy and safety of fenebrutinib in adults with progressive ms
Genentech, Inc. - Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141486 - TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis
Tg Therapeutics, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.